Skip header and navigation

Refine By

24 records – page 1 of 3.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

https://arctichealth.org/en/permalink/ahliterature265750
Source
Lancet. 2015 Aug 1;386(9992):433-43
Publication Type
Article
Date
Aug-1-2015
Author
Michael Gnant
Georg Pfeiler
Peter C Dubsky
Michael Hubalek
Richard Greil
Raimund Jakesz
Viktor Wette
Marija Balic
Ferdinand Haslbauer
Elisabeth Melbinger
Vesna Bjelic-Radisic
Silvia Artner-Matuschek
Florian Fitzal
Christian Marth
Paul Sevelda
Brigitte Mlineritsch
Günther G Steger
Diether Manfreda
Ruth Exner
Daniel Egle
Jonas Bergh
Franz Kainberger
Susan Talbot
Douglas Warner
Christian Fesl
Christian F Singer
Source
Lancet. 2015 Aug 1;386(9992):433-43
Date
Aug-1-2015
Language
English
Publication Type
Article
Keywords
Absorptiometry, Photon
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - therapeutic use
Aromatase Inhibitors - therapeutic use
Austria
Bone Density - physiology
Breast Neoplasms - complications - drug therapy
Double-Blind Method
Female
Fractures, Bone - complications - prevention & control
Humans
Middle Aged
Postmenopause
Prospective Studies
Receptors, Estrogen - metabolism
Receptors, Progesterone - metabolism
Sweden
Treatment Outcome
Abstract
Adjuvant endocrine therapy compromises bone health in patients with breast cancer, causing osteopenia, osteoporosis, and fractures. Antiresorptive treatments such as bisphosphonates prevent and counteract these side-effects. In this trial, we aimed to investigate the effects of the anti-RANK ligand antibody denosumab in postmenopausal, aromatase inhibitor-treated patients with early-stage hormone receptor-positive breast cancer.
In this prospective, double-blind, placebo-controlled, phase 3 trial, postmenopausal patients with early hormone receptor-positive breast cancer receiving treatment with aromatase inhibitors were randomly assigned in a 1:1 ratio to receive either denosumab 60 mg or placebo administered subcutaneously every 6 months in 58 trial centres in Austria and Sweden. Patients were assigned by an interactive voice response system. The randomisation schedule used a randomly permuted block design with block sizes 2 and 4, stratified by type of hospital regarding Hologic device for DXA scans, previous aromatase inhibitor use, and baseline bone mineral density. Patients, treating physicians, investigators, data managers, and all study personnel were masked to treatment allocation. The primary endpoint was time from randomisation to first clinical fracture, analysed by intention to treat. As an additional sensitivity analysis, we also analysed the primary endpoint on the per-protocol population. Patients were treated until the prespecified number of 247 first clinical fractures was reached. This trial is ongoing (patients are in follow-up) and is registered with the European Clinical Trials Database, number 2005-005275-15, and with ClinicalTrials.gov, number NCT00556374.
Between Dec 18, 2006, and July 22, 2013, 3425 eligible patients were enrolled into the trial, of whom 3420 were randomly assigned to receive denosumab 60 mg (n=1711) or placebo (n=1709) subcutaneously every 6 months. Compared with the placebo group, patients in the denosumab group had a significantly delayed time to first clinical fracture (hazard ratio [HR] 0·50 [95% CI 0·39-0·65], p
Notes
Comment In: Lancet. 2015 Aug 1;386(9992):409-1026040500
PubMed ID
26040499 View in PubMed
Less detail

Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.

https://arctichealth.org/en/permalink/ahliterature101025
Source
Breast Cancer Res Treat. 2011 May 27;
Publication Type
Article
Date
May-27-2011
Author
Theodoros Foukakis
Tommy Fornander
Tobias Lekberg
Henrik Hellborg
Jan Adolfsson
Jonas Bergh
Author Affiliation
Department of Oncology-Pathology, Radiumhemmet, Karolinska Institutet, Karolinska University Hospital, 17176, Stockholm, Sweden, theodoros.foukakis@ki.se.
Source
Breast Cancer Res Treat. 2011 May 27;
Date
May-27-2011
Language
English
Publication Type
Article
Abstract
Treatment of metastatic breast cancer (MBC) has evolved during the last decades but it is largely unknown whether this has led to improved survival in the general MBC population. Based on the regional, population-based breast cancer registry, we identified 5,463 patients diagnosed with MBC in Stockholm County during 1979-2004. Patients were divided into five cohorts based on the year of first MBC diagnosis and observed and relative survival were compared across the cohorts after adjustment for potential confounders. A significant trend of better survival over time was demonstrated for patients 60 years or younger (P 
PubMed ID
21617918 View in PubMed
Less detail

Attainment and importance of life values among patients with primary breast cancer.

https://arctichealth.org/en/permalink/ahliterature18288
Source
Cancer Nurs. 2003 Aug;26(4):295-304
Publication Type
Article
Date
Aug-2003
Author
Claudia Lampic
Erik Thurfjell
Jonas Bergh
Marianne Carlsson
Per-Olow Sjödén
Author Affiliation
Department of Public Health and Caring Sciences, Section of Caring Sciences, Uppsala University, Uppsala Science Park, SE-751 83 Uppsala, Sweden. claudia.lampic@pubcare.lu.se
Source
Cancer Nurs. 2003 Aug;26(4):295-304
Date
Aug-2003
Language
English
Publication Type
Article
Keywords
Adaptation, Psychological
Adult
Age Factors
Aged
Attitude to Health
Breast Neoplasms - diagnosis - psychology
Case-Control Studies
Female
Goals
Health Knowledge, Attitudes, Practice
Humans
Life Change Events
Marital status
Middle Aged
Mothers - psychology
Nursing Methodology Research
Prospective Studies
Questionnaires
Research Support, Non-U.S. Gov't
Self Concept
Social Values
Sweden
Women - psychology
Abstract
The main aims of this study were to investigate the extent to which women with recently diagnosed primary breast cancer (N = 29) and matched control subjects without cancer (N = 29) differ in perceived attainment and importance of life values and to study prospectively life value ratings during 1 year in a large group of recent attendees at mammography screening (N = 706). Life values were assessed by a study-specific version of a life value questionnaire, including ratings of the perceived attainment and importance of seven life value dimensions. Women with a recent diagnosis of primary breast cancer were found to attribute significantly more importance to positive relations than healthy controls. No other differences between these groups were found regarding the attainment or importance of life values. Perceptions of life values were found to vary as a function of age, marital or cohabitation status, and parenthood, and to be stable over a 9-month period in screening attendees. The implications of the current findings for the understanding of women's psychological adaptation to breast cancer are discussed.
PubMed ID
12886120 View in PubMed
Less detail

Breast cancer in young women and prognosis: How important are proliferation markers?

https://arctichealth.org/en/permalink/ahliterature286255
Source
Eur J Cancer. 2017 Oct;84:278-289
Publication Type
Article
Date
Oct-2017

Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial.

https://arctichealth.org/en/permalink/ahliterature16658
Source
J Natl Cancer Inst. 2005 Nov 2;97(21):1609-10
Publication Type
Article
Date
Nov-2-2005
Author
Bo Nordenskjöld
Johan Rosell
Lars-Erik Rutqvist
Per-Olof Malmström
Jonas Bergh
Nils-Olof Bengtsson
Thomas Hatschek
Arne Wallgren
John Carstensen
Author Affiliation
Department of Oncology, Linköping University Hospital, Linköping, Sweden. bo.nordenskjold@lio.se
Source
J Natl Cancer Inst. 2005 Nov 2;97(21):1609-10
Date
Nov-2-2005
Language
English
Publication Type
Article
Keywords
Aged
Antineoplastic Agents, Hormonal - administration & dosage
Breast Neoplasms - drug therapy - prevention & control
Chemotherapy, Adjuvant
Coronary Disease - mortality
Drug Administration Schedule
Estrogen Receptor Modulators - administration & dosage
Female
Humans
Incidence
Middle Aged
Mortality - trends
Odds Ratio
Postmenopause
Proportional Hazards Models
Registries
Research Support, Non-U.S. Gov't
Sweden - epidemiology
Tamoxifen - administration & dosage
Time Factors
Abstract
From January 1, 1983, through December 31, 1992, a total of 4610 patients entered a randomized trial that compared mortality among patients receiving 2 years of adjuvant tamoxifen therapy with that in patients receiving 5 years of adjuvant tamoxifen therapy, 4175 of whom were recurrence free after 2 years of tamoxifen therapy. Among the 2046 patients randomly assigned to the 5-year group all-cause mortality, breast cancer-specific mortality, and the incidence of contralateral breast cancer were reduced, compared with those among 2129 patients randomized in the 2-year group, but the incidence of endometrial cancer was increased. In addition, mortality from coronary heart disease was statistically significantly reduced in the 5-year group, compared with that in the 2-year group (hazard ratio = 0.67, 95% confidence interval = 0.47 to 0.94; P = .022 [two-sided Wald test]). Ten years after surgery, 2.1% of the patients in the 5-year group and 3.5% of those in the 2-year group had died from coronary heart disease. No statistically significant increases in mortality from other heart diseases, cerebrovascular diseases, or other vascular diseases were observed.
PubMed ID
16264181 View in PubMed
Less detail

Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.

https://arctichealth.org/en/permalink/ahliterature137287
Source
Acta Oncol. 2011 Apr;50(3):329-37
Publication Type
Article
Date
Apr-2011
Author
Per Edlund
Johan Ahlgren
Karsten Bjerre
Michael Andersson
Jonas Bergh
Henning Mouridsen
Stig B Holmberg
Nils-Olof Bengtsson
Erik Jakobsen
Susanne Møller
Henrik Lindman
Carl Blomqvist
Author Affiliation
Department of Oncology, Gävle Hospital, Sweden.
Source
Acta Oncol. 2011 Apr;50(3):329-37
Date
Apr-2011
Language
English
Publication Type
Article
Keywords
Adult
Antineoplastic Combined Chemotherapy Protocols - administration & dosage - adverse effects
Breast Neoplasms - drug therapy - surgery
Carcinoma - drug therapy - surgery
Chemotherapy, Adjuvant - methods
Cyclophosphamide - administration & dosage - adverse effects
Dose-Response Relationship, Drug
Epirubicin - administration & dosage - adverse effects
Feasibility Studies
Female
Fluorouracil - administration & dosage - adverse effects
Humans
Individuality
Individualized Medicine - methods
Leukopenia - chemically induced - epidemiology - prevention & control
Mastectomy
Maximum Tolerated Dose
Middle Aged
Scandinavia
Severity of Illness Index
Treatment Outcome
Abstract
The SBG 2000-1 trial is a randomised study that investigates if dose-tailored adjuvant FEC therapy based on the individual's leukocyte nadir value can improve outcome. The study has included 1535 women with medium and high-risk breast cancer.
After a first standard dosed FEC course (5-fluorouracil 600 mg/m(2), epirubicin 60 mg/mg(2) and cyclophosphamide 600 mg/m(2)), patients who did not reach leukopenia grade III or IV were randomised to standard doses (group standard) or doses tailored to achieve grade III leukopenia (group tailored) at courses 2-7. Patients who achieved leukopenia grade III or more after the first course were not randomised but continued on standard doses (group registered).
Both planned and actually delivered number of courses (seven) were the same in all three arms. The relative dose intensity was increased by a factor of 1.31 (E 1.22, C 1.43) for patients in the tailored arm compared to the expected on standard dose. Ninety percent of the patients in the tailored arm achieved leukopenia grade III-IV compared with 29% among patients randomised to standard dosed therapy. Dose tailoring was associated with acceptable acute non-haematological toxicity with more total alopecia, nausea, vomiting and fatigue.
Dose tailoring according to leukopenia was feasible. It led to an increased dose intensity and was associated with acceptable excess of acute non-haematological toxicity.
PubMed ID
21299448 View in PubMed
Less detail

Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity.

https://arctichealth.org/en/permalink/ahliterature17061
Source
Acta Oncol. 2005;44(1):41-9
Publication Type
Article
Date
2005
Author
Johanna Smeds
Fredrik Wärnberg
Torbjörn Norberg
Hans Nordgren
Lars Holmberg
Jonas Bergh
Author Affiliation
Department of Oncology-Pathology, Radiumhemmet Cancer Centre Karolinska, Karolinska Institute and Hospital, S-171 76 Stockholm, Sweden. johanna.smeds@cck.ki.se
Source
Acta Oncol. 2005;44(1):41-9
Date
2005
Language
English
Publication Type
Article
Keywords
Breast Neoplasms - genetics - mortality - pathology
Carcinoma, Intraductal, Noninfiltrating - genetics - mortality - pathology
Case-Control Studies
Comparative Study
Female
Genetic Markers - genetics
Humans
Loss of Heterozygosity - genetics
Microsatellite Repeats
Neoplasm Invasiveness - genetics - pathology
Neoplasm Staging
Polymerase Chain Reaction - methods
Prognosis
Reference Values
Research Support, Non-U.S. Gov't
Risk assessment
Sensitivity and specificity
Sweden
Abstract
To compare chromosomal alterations in ductal carcinoma in situ (DCIS) of different histopathological grades and to study aberrations between primary DCIS and corresponding ipsi- or contralateral new in situ or invasive tumours, a study was undertaken of the pattern of loss of heterozygosity (LOH) at chromosomal regions in which LOH has previously been described in invasive breast cancer. LOH was analysed using 19 microsatellite markers located on chromosomes 3p, 6q, 8p, 8q, 9p, 11p, 11q, 16q, 17p, and 17q in 30 women with a primary DCIS. Eleven women with DCIS of grade 1 and 19 with grade 3 according to the EORTC classification system were included. In six patients LOH was also analysed in a subsequent new breast cancer. Fractional allelic loss (FAL, the ratio of chromosomal arms where allelic loss was detected divided by the total number of chromosomal arms with informative markers) was statistically significantly higher in grade 1 DCIS compared with grade 3 (p=0.02) for the 19 loci, indicating that the amount of allelic loss does not correlate with increasing aggressiveness of the studied tumours. Also observed was a complete heterogeneity of LOH in the primary DCIS and their corresponding new events, suggesting that these events probably developed from genetically divergent clones.
PubMed ID
15848905 View in PubMed
Less detail

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

https://arctichealth.org/en/permalink/ahliterature277996
Source
JAMA. 2016 Nov 08;316(18):1888-1896
Publication Type
Article
Date
Nov-08-2016
Author
Theodoros Foukakis
Gunter von Minckwitz
Nils-Olof Bengtsson
Yvonne Brandberg
Birgitta Wallberg
Tommy Fornander
Brigitte Mlineritsch
Sabine Schmatloch
Christian F Singer
Günther Steger
Daniel Egle
Eva Karlsson
Lena Carlsson
Sibylle Loibl
Michael Untch
Mats Hellström
Hemming Johansson
Harald Anderson
Per Malmström
Michael Gnant
Richard Greil
Volker Möbus
Jonas Bergh
Source
JAMA. 2016 Nov 08;316(18):1888-1896
Date
Nov-08-2016
Language
English
Publication Type
Article
Keywords
Adult
Aged
Antibiotics, Antineoplastic - administration & dosage - adverse effects
Antineoplastic Agents - administration & dosage - adverse effects - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - administration & dosage - adverse effects - therapeutic use
Austria
Breast Neoplasms - drug therapy - mortality - pathology
Chemotherapy, Adjuvant - adverse effects - methods
Cyclophosphamide - administration & dosage
Disease-Free Survival
Drug Administration Schedule
Epirubicin - administration & dosage
Female
Fluorouracil - administration & dosage
Germany
Humans
Middle Aged
Neoplasm Recurrence, Local
Quality of Life
Sweden
Taxoids - administration & dosage
Abstract
Standard dosing of chemotherapy based on body surface area results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy. Whether tailored dosing can improve outcomes is unknown, as is the role of dose-dense adjuvant chemotherapy.
To determine whether tailored dose-dense adjuvant chemotherapy improves the outcomes of early breast cancer compared with a standard 3-weekly chemotherapy schedule.
A randomized, open-label, phase 3 trial of women aged 65 years and younger who had surgery for nonmetastatic node-positive or high-risk node-negative breast cancer at 86 sites in Sweden, Germany, and Austria between February 20, 2007, and September 14, 2011.
Patients were randomized 1:1 either to 4 cycles of leukocyte nadir-based tailored and dose-dense adjuvant epirubicin and cyclophosphamide every 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks, or to standard-interval chemotherapy with 3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3 cycles of docetaxel every 3 weeks.
The primary end point was breast cancer recurrence-free survival (BCRFS). Secondary end points included 5-year event-free survival (EFS), distant disease-free survival (DDFS), overall survival (OS), and rates of grade 3 or 4 toxic effects.
Among 2017 randomized patients (1006 in the tailored dose-dense group and 1011 in the control group; median [IQR] age, 51 [45-58] years; 80% with hormone receptor-positive tumors; 97% with node-positive disease), 2000 received study treatment (=1 cycle of chemotherapy; 1001 in the tailored dose-dense group and 999 in the control group). After a median follow-up of 5.3 years (IQR, 4.5-6.1 years), 269 BCRFS events were reported, 118 in the tailored dose-dense group and 151 in the control group (HR, 0.79; 95% CI, 0.61-1.01; log-rank P?=?.06; 5-year BCRFS, 88.7% vs 85.0%). The tailored dose-dense group had significantly better EFS than the control group (HR, 0.79; 95% CI, 0.63-0.99; P?=?.04; 5-year EFS, 86.7% vs 82.1%). The groups did not differ in OS (HR, 0.77; 95% CI, 0.57-1.05; P?=?.09; 5-year OS, 92.1% vs 90.2%) or DDFS (HR, 0.83; 95% CI, 0.64-1.08; P?=?.17; 5-year DDFS, 89.4% vs 86.7%). Grade 3 or 4 nonhematologic toxic effects occurred in 527 (52.6%) in the tailored dose-dense group and 366 (36.6%) in the control group.
Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival. Nonhematologic toxic effects were more frequent in the tailored dose-dense group.
clinicaltrials.gov Identifier: NCT00798070; isrctn.org Identifier: ISRCTN39017665.
Notes
Comment In: JAMA. 2016 Nov 8;316(18):1877-187827723886
PubMed ID
27825007 View in PubMed
Less detail

Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.

https://arctichealth.org/en/permalink/ahliterature312069
Source
Hum Reprod. 2020 04 28; 35(4):929-938
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
04-28-2020
Author
Anna Marklund
Sandra Eloranta
Ida Wikander
Margareta Laczna Kitlinski
Mikael Lood
Elizabeth Nedstrand
Ann Thurin-Kjellberg
Pu Zhang
Jonas Bergh
Kenny A Rodriguez-Wallberg
Author Affiliation
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Source
Hum Reprod. 2020 04 28; 35(4):929-938
Date
04-28-2020
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Breast Neoplasms - drug therapy
Female
Fertility Preservation
Gonadotropin-Releasing Hormone
Humans
Multicenter Studies as Topic
Ovulation Induction
Pregnancy
Prospective Studies
Sweden
Abstract
How efficacious and safe are the current approaches to controlled ovarian stimulation (COS) aimed at fertility preservation (FP) in women with breast cancer (BC)?
In women with BC undergoing COS aiming at egg/embryo cryopreservation, letrozole-based protocols and those randomly started were equally effective compared with conventional COS, and the overall survival was similar between the women that proceeded to FP and those who did not.
Cryopreservation of oocytes and embryos is an established method for FP in women with BC. Recent improvements to COS protocols include concomitant use of letrozole, random-cycle start day of stimulation and the use of GnRHa for the egg maturation trigger. To date, limited sample size of the available studies has not allowed investigation of differences in the efficacy of the different approaches to COS for FP in this patient population.
A prospective multicenter study with national coverage including 610 women with BC counseled between 1 January 1995 and 30 June 2017 at six Swedish FP regional programs.
After counseling, 401 women elected to undergo COS. Treatments differed in the use or not of concomitant letrozole, a conventional or random-cycle day COS initiation and the use of hCG versus GnRHa trigger for oocyte maturation. Numbers of cryopreserved oocytes and embryos were defined as primary outcome. Pregnancy attempts, reproductive outcomes and long-term survival, investigated by the linking of individuals of the cohort to the total population register of the Swedish Tax Agency (up to 25 November 2018), were evaluated.
Using letrozole or not resulted in similar numbers of oocytes and embryos cryopreserved (meanoocytes?=?9.7 versus 10 and meanembryos 4.0 versus 5.3, respectively), similar to COS with random versus conventional start (meanoocytes 9.0 versus 10.6 and meanembryos 4.8 versus 4.8). In COS with letrozole, a GnRHa trigger was associated with a higher number of oocytes retrieved (P?
PubMed ID
32313940 View in PubMed
Less detail

Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.

https://arctichealth.org/en/permalink/ahliterature16643
Source
Breast Cancer Res. 2005;7(6):R953-64
Publication Type
Article
Date
2005
Author
Yudi Pawitan
Judith Bjöhle
Lukas Amler
Anna-Lena Borg
Suzanne Egyhazi
Per Hall
Xia Han
Lars Holmberg
Fei Huang
Sigrid Klaar
Edison T Liu
Lance Miller
Hans Nordgren
Alexander Ploner
Kerstin Sandelin
Peter M Shaw
Johanna Smeds
Lambert Skoog
Sara Wedrén
Jonas Bergh
Author Affiliation
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Yudi.Pawitan@meb.ki.se
Source
Breast Cancer Res. 2005;7(6):R953-64
Date
2005
Language
English
Publication Type
Article
Keywords
Adult
Aged
Breast Neoplasms - drug therapy - genetics - surgery
Chemotherapy, Adjuvant
Cohort Studies
Female
Gene Expression Profiling
Genes, Neoplasm
Humans
Middle Aged
Neoplasm Metastasis
Netherlands
Odds Ratio
Prognosis
Research Support, Non-U.S. Gov't
Survival Analysis
Sweden
Treatment Outcome
Abstract
INTRODUCTION: Adjuvant breast cancer therapy significantly improves survival, but overtreatment and undertreatment are major problems. Breast cancer expression profiling has so far mainly been used to identify women with a poor prognosis as candidates for adjuvant therapy but without demonstrated value for therapy prediction. METHODS: We obtained the gene expression profiles of 159 population-derived breast cancer patients, and used hierarchical clustering to identify the signature associated with prognosis and impact of adjuvant therapies, defined as distant metastasis or death within 5 years. Independent datasets of 76 treated population-derived Swedish patients, 135 untreated population-derived Swedish patients and 78 Dutch patients were used for validation. The inclusion and exclusion criteria for the studies of population-derived Swedish patients were defined. RESULTS: Among the 159 patients, a subset of 64 genes was found to give an optimal separation of patients with good and poor outcomes. Hierarchical clustering revealed three subgroups: patients who did well with therapy, patients who did well without therapy, and patients that failed to benefit from given therapy. The expression profile gave significantly better prognostication (odds ratio, 4.19; P = 0.007) (breast cancer end-points odds ratio, 10.64) compared with the Elston-Ellis histological grading (odds ratio of grade 2 vs 1 and grade 3 vs 1, 2.81 and 3.32 respectively; P = 0.24 and 0.16), tumor stage (odds ratio of stage 2 vs 1 and stage 3 vs 1, 1.11 and 1.28; P = 0.83 and 0.68) and age (odds ratio, 0.11; P = 0.55). The risk groups were consistent and validated in the independent Swedish and Dutch data sets used with 211 and 78 patients, respectively. CONCLUSION: We have identified discriminatory gene expression signatures working both on untreated and systematically treated primary breast cancer patients with the potential to spare them from adjuvant therapy.
PubMed ID
16280042 View in PubMed
Less detail

24 records – page 1 of 3.